A high-throughput functional complementation assay for classification of BRCA1 missense variants

Cancer Discovery

Volumn 3, Issue 10, 2013, Pages 1142-1155

  Bouwman, Peter ^a   van der Gulden, Hanneke ^a   van der Heijden, Ingrid ^a   Drost, Rinske ^a   Klijn, Christiaan N ^a,c   Prasetyanti, Pramudita ^a   Pieterse, Mark ^a   Wientjens, Ellen ^a   Seibler, Jost ^b   Hogervorst, Frans B L ^a   Jonkers, Jos ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b TaconicArtemis GmbH   (Germany)

^c GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; COMPLEMENTARY DNA; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OLAPARIB;

AMINO ACID SEQUENCE; ANIMAL CELL; ARTICLE; BACTERIAL ARTIFICIAL CHROMOSOME; BREAST CANCER; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DNA END JOINING REPAIR; DRUG SENSITIVITY; GENE EXPRESSION; GENE SEQUENCE; GENETIC VARIABILITY; GENOMIC INSTABILITY; HIGH THROUGHPUT SEQUENCING; HUMAN; MISSENSE MUTATION; MOUSE; NONHUMAN; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

AMINO ACID SEQUENCE; ANIMALS; ANTINEOPLASTIC AGENTS; BRCA1 PROTEIN; BREAST NEOPLASMS; CELL PROLIFERATION; CISPLATIN; DNA REPAIR; DRUG SCREENING ASSAYS, ANTITUMOR; EMBRYONIC STEM CELLS; FEMALE; GENES, BRCA1; GENETIC COMPLEMENTATION TEST; GENETIC VARIATION; HIGH-THROUGHPUT SCREENING ASSAYS; HOMOLOGOUS RECOMBINATION; HUMANS; MICE; MICE, KNOCKOUT; MOLECULAR SEQUENCE DATA; MUTAGENESIS, SITE-DIRECTED; MUTATION, MISSENSE; OVARIAN NEOPLASMS; PHTHALAZINES; PIPERAZINES; POLY(ADP-RIBOSE) POLYMERASES; RING FINGER DOMAINS;

EID: 84885593414     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-13-0094     Document Type: Article

References (49)

1. Spurdle AB, Healey S, Devereau A, Hogervorst FBL, Monteiro ANA, Nathanson KL, et al. ENIGMA-evidence-based network for the interpretation of germline mutant alleles: an international initiative to evaluate risk and clinical significance associated with sequence variation in BRCA1 and BRCA2 genes. Hum Mutat 2012; 33: 2-7.
2. Lindor NM, Guidugli L, Wang X, Vallée MP, Monteiro ANA, Tavtigian S, et al. A review of a multifactorial probability-based model for classification of BRCA1 and BRCA2 variants of uncertain signifi- cance (VUS). Hum Mutat 2012; 33: 8-21.
3. Millot GA, Carvalho MA, Caputo SM, Vreeswijk MPG, Brown MA, Webb M, et al. A guide for functional analysis of BRCA1 variants of uncertain significance. Hum Mutat 2012; 33: 1526-1537.
4. Evers B, Jonkers J. Mouse models of BRCA1 and BRCA2 deficiency: past lessons, current understanding and future prospects. Oncogene 2006; 25: 5885-5897.
5. Bouwman P, Aly A, Escandell JM, Pieterse M, Bartkova J, Van der Gulden H, et al. 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers. Nat Struct Mol Biol 2010; 17: 688-695.
6. Seibler J, Küter-Luks B, Kern H, Streu S, Plum L, Mauer J, et al. Single copy shRNA configuration for ubiquitous gene knockdown in mice. Nucleic Acids Res 2005; 33: e67.
7. Chang S, Biswas K, Martin BK, Stauffer S, Sharan SK. Expression of human BRCA1 variants in mouse ES cells allows functional analysis of BRCA1 mutations. J Clin Invest 2009; 119: 3160-3171.
8. Lee MS, Green R, Marsillac SM, Coquelle N, Williams RS, Yeung T, et al. Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays. Cancer Res 2010; 70: 4880-4890.
9. Easton DF, Deffenbaugh AM, Pruss D, Frye C, Wenstrup RJ, Allen- Brady K, et al. A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes. Am J Hum Genet 2007; 81: 873-883.
10. Sy SMH, Huen MSY, Chen J. PALB2 is an integral component of the BRCA complex required for homologous recombination repair. Proc Natl Acad Sci U S A 2009; 106: 7155-7160.
11. Tavtigian SV, Deffenbaugh AM, Yin L, Judkins T, Scholl T, Samollow PB, et al. Comprehensive statistical study of 452 BRCA1 missense substitutions with classification of eight recurrent substitutions as neutral. J Med Genet 2006; 43: 295-305.
12. Moynahan ME, Pierce AJ, Jasin M. BRCA2 is required for homologydirected repair of chromosomal breaks. Mol Cell 2001; 7: 263-272.
13. Chandler J, Hohenstein P, Swing DA, Tessarollo L, Sharan SK. Human BRCA1 gene rescues the embryonic lethality of Brca1 mutant mice. Genesis 2001; 29: 72-77.
14. De Nicolo A, Parisini E, Zhong Q, Dalla Palma M, Stoeckert KA, Domchek SM, et al. Multimodal assessment of protein functional deficiency supports pathogenicity of BRCA1 p.V1688del. Cancer Res 2009; 69: 7030-7037.
15. Rowling PJE, Cook R, Itzhaki LS. Toward classification of BRCA1 missense variants using a biophysical approach. J Biol Chem 2010; 285: 20080-7.
16. Bunting SF, Callén E, Kozak ML, Kim JM, Wong N, López-Contreras AJ, et al. BRCA1 functions independently of homologous recombination in DNA interstrand crosslink repair. Mol Cell 2012; 46: 125-135.
17. Norquist B, Wurz KA, Pennil CC, Garcia R, Gross J, Sakai W, et al. Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas. J Clin Oncol 2011; 29: 3008-3015.
18. Swisher EM, Sakai W, Karlan BY, Wurz K, Urban N, Taniguchi T. Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance. Cancer Res 2008; 68: 2581-2586.
19. Houdayer C, Caux-Moncoutier V, Krieger S, Barrois M, Bonnet F, Bourdon V, et al. Guidelines for splicing analysis in molecular diagnosis derived from a set of 327 combined in silico / in vitro studies on BRCA1 and BRCA2 variants. Hum Mutat 2012; 33: 1228-1238.
20. Houdayer C, Dehainault C, Mattler C, Michaux D, Caux-Moncoutier V, Pagès-Berhouet S, et al. Evaluation of in silico splice tools for decision- making in molecular diagnosis. Hum Mutat 2008; 29: 975-982.
21. Moynahan ME, Chiu JW, Koller BH, Jasin M. Brca1 controls homology- directed DNA repair. Mol Cell 1999; 4: 511-518.
22. Schlacher K, Wu H, Jasin M. A distinct replication fork protection pathway connects Fanconi anemia tumor suppressors to RAD51- BRCA1/2. Cancer Cell 2012; 22: 106-116.
23. Joukov V, Groen AC, Prokhorova T, Gerson R, White E, Rodriguez A, et al. The BRCA1/BARD1 heterodimer modulates ran-dependent mitotic spindle assembly. Cell 2006; 127: 539-552.
24. Zhu Q, Pao GM, Huynh AM, Suh H, Tonnu N, Nederlof PM, et al. BRCA1 tumour suppression occurs via heterochromatin-mediated silencing. Nature 2011; 477: 179-184.
25. Shakya R, Reid LJ, Reczek CR, Cole F, Egli D, Lin C-S, et al. BRCA1 tumor suppression depends on BRCT phosphoprotein binding, but not its E3 ligase activity. Science 2011; 334: 525-528.
26. Drost R, Bouwman P, Rottenberg S, Boon U, Schut E, Klarenbeek S, et al. BRCA1 RING function is essential for tumor suppression but dispensable for therapy resistance. Cancer Cell 2011; 20: 797-809.
27. Pierce AJ, Johnson RD, Thompson LH, Jasin M. XRCC3 promotes homology-directed repair of DNA damage in mammalian cells. Genes Dev 1999; 13: 2633-2638.
28. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005; 434: 913-917.
29. Farmer H, McCabe N, Lord CJ, Tutt ANJ, Johnson DA, Richardson TB, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005; 434: 917-921.
30. Evers B, Schut E, Van der Burg E, Braumuller TM, Egan DA, Holstege H, et al. A high-throughput pharmaceutical screen identifies compounds with specific toxicity against BRCA2-deficient tumors. Clin Cancer Res 2010; 16: 99-108.
31. Domchek SM, Tang J, Stopfer J, Lilli DR, Hamel N, Tischkowitz M, et al. Biallelic deleterious BRCA1 mutations in a woman with earlyonset ovarian cancer. Cancer Discov 2013; 3: 399-405.
32. Spurdle AB, Whiley PJ, Thompson B, Feng B, Healey S, Brown MA, et al. BRCA1 R1699Q variant displaying ambiguous functional abrogation confers intermediate breast and ovarian cancer risk. J Med Genet 2012; 49: 525-532.
33. Morris JR, Pangon L, Boutell C, Katagiri T, Keep NH, Solomon E. Genetic analysis of BRCA1 ubiquitin ligase activity and its relationship to breast cancer susceptibility. Hum Mol Genet 2006; 15: 599-606.
34. Ransburgh DJR, Chiba N, Ishioka C, Toland AE, Parvin JD. Identification of breast tumor mutations in BRCA1 that abolish its function in homologous DNA recombination. Cancer Res 2010; 70: 988-995.
35. Au WWY, Henderson BR. The BRCA1 RING and BRCT domains cooperate in targeting BRCA1 to ionizing radiation-induced nuclear foci. J Biol Chem 2005; 280: 6993-7001.
36. Manié E, Vincent-Salomon A, Lehmann-Che J, Pierron G, Turpin E, Warcoin M, et al. High frequency of TP53 mutation in BRCA1 and sporadic basal-like carcinomas but not in BRCA1 luminal breast tumors. Cancer Res 2009; 69: 663-671.
37. Holstege H, Joosse SA, Van Oostrom CTM, Nederlof PM, De Vries A, Jonkers J. High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer. Cancer Res 2009; 69: 3625-3633.
38. Bunting SF, Callén E, Wong N, Chen H-T, Polato F, Gunn A, et al. 53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks. Cell 2010; 141: 243-254.
39. Cao L, Xu X, Bunting SF, Liu J, Wang R-H, Cao LL, et al. A selective requirement for 53BP1 in the biological response to genomic instability induced by Brca1 deficiency. Mol Cell 2009; 35: 534-41.
40. Kuznetsov SG, Liu P, Sharan SK. Mouse embryonic stem cellbased functional assay to evaluate mutations in BRCA2. Nat Med 2008; 14: 875-881.
41. Li M, Yu X. Function of BRCA1 in the DNA damage response is mediated by ADP-ribosylation. Cancer Cell 2013; 23: 693-704.
42. Kornblihtt AR, Schor IE, Alló M, Dujardin G, Petrillo E, Muñoz MJ. Alternative splicing: a pivotal step between eukaryotic transcription and translation. Nat Rev Mol Cell Biol 2013; 14: 153-165.
43. Wessels LFA, Van Welsem T, Hart AAM, Van't Veer LJ, Reinders MJT, Nederlof PM. Molecular classification of breast carcinomas by comparative genomic hybridization: a specific somatic genetic profile for BRCA1 tumors. Cancer Res 2002; 62: 7110-7117.
44. Van Beers EH, Van Welsem T, Wessels LFA, Li Y, Oldenburg RA, Devilee P, et al. Comparative genomic hybridization profiles in human BRCA1 and BRCA2 breast tumors highlight differential sets of genomic aberrations. Cancer Res 2005; 65: 822-7.
45. Chen J, Silver DP, Walpita D, Cantor SB, Gazdar AF, Tomlinson G, et al. Stable interaction between the products of the BRCA1 and BRCA2 tumor suppressor genes in mitotic and meiotic cells. Mol Cell 1998; 2: 317-328.
46. Robanus-Maandag E, Dekker M, Van der Valk M, Carrozza ML, Jeanny JC, Dannenberg JH, et al. p107 is a suppressor of retinoblastoma development in pRb-deficient mice. Genes Dev 1998; 12: 1599-1609.
47. Liu X, Holstege H, Van der Gulden H, Treur-Mulder M, Zevenhoven J, Velds A, et al. Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer. Proc Natl Acad Sci U S A 2007; 104: 12111-12116.
48. Buchholz F, Angrand PO, Stewart AF. Improved properties of FLP recombinase evolved by cycling mutagenesis. Nat Biotechnol 1998; 16: 657-662.
49. Puppe J, Drost R, Liu X, Joosse SA, Evers B, Cornelissen-Steijger P, et al. BRCA1-deficient mammary tumor cells are dependent on EZH2 expression and sensitive to Polycomb Repressive Complex 2-inhibitor 3-deazaneplanocin A. Breast Cancer Res 2009; 11: R63.